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To investigate the possible modulatory effect of the immune response induced by recurrent
carcinogen exposure, a specific humoral immune response toward 2-acetylaminofluorene (2-AAF)
was elicited in Swiss mice with repeated intraperitoneal injections of a 2-AAF-gelatin conjugate.
The immunization procedure resulted in the production of specific anti-2-AAF antibodies in all
treated animals. Groups of immunized and nonimmunized mice were subsequently fed 2-AAF
pelleted in the diet at 50 and 150 ppm for 4 weeks. At the end of 2-MF administration, animals
were sacrificed and the content of 2-AAF-adducts in liver DNA was determined by enzyme-linked
immunoadsorbent assay using a polyclonal rabbit antiserum. The comparison of the adduct levels
in immunized and nonimmunized mice (receiving either the vehicle or the adjuvant alone during
pretreatment) demonstrates a highly significant (p<0.001) difference among groups, with far
lower adduct levels in immunized animals. No significant difference in food consumption or liver
metabolic activities was observed among experimental groups, suggesting the absence of
external bias. The mechanism underlying the result observed is not yet clear; however, the exper-
imental data strongly suggest that the specific immunological response induced by recurrent
carcinogen exposure may exert a modulatory effect and act as a relevant host factor in chemical
carcinogenesis. Environ Health Perspect 104(Suppl 3):679-682 (1996)
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Introduction
Manifold inherited and acquired host fac-
tors such as variance in DNA repair (1-3)
and xenobiotic metabolism (4-6), age,
nutrition, stress, diseases, hormonal status
(7-8), and immunological (9) and genetic
factors (10,11) are known to affect the
individual response to chemical carcinogens
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(12-14). Another significant trait might be
represented by the immunological response
elicited by the formation of adducts to
macromolecules during chronic carcinogen
exposure. In this regard, previous studies
demonstrated the presence of antibodies
directed against benzopyrene-DNA adduct
in blood sera of humans occupationally
exposed to high levels ofpolycyclic aro-
matic hydrocarbons (PAHs) (15-16) and
in the urban population (17). Conse-
quently, this trait has been proposed as a
retrospective individual exposure marker in
biomonitoring studies (18). On the other
hand, it has not yet been elucidated whether
such induced immune response may play
some mechanistic role, such as modulating
the effect produced by the carcinogen
itself. An interesting clue to this possibility
was previously provided by the observation
of a protective effect of the secretory
immune response to 2-acetylaminofluorene
(2-AAF) in rabbits, possibly related to the
reduction in transepithelial absorption of
the carcinogen (19).
To investigate the potential significance
ofthe humoral anticarcinogen immunity, a
specific immunological response toward
2-AAF was elicited in Swiss mice. Both
immunized and nonimmunized animals
were subsequently challenged with a
4-week dietary exposure to the carcinogen.
At the end oftreatment, 2-AAF binding to
liver DNA was determined in all animals
and evaluated in relation to their immune
status and carcinogen exposure.
Methods
Animas
Male Swiss mice (Charles River, Calco,
Como, Italy), 4 weeks ofage at the begin-
ning of treatment, were maintained on a
balanced standard chow (Mucedola,
Milan, Italy) and tap water ad libitum.
Animal care, treatments, and sacrifice
were conducted in strict accordance with
Directive 86/609/EEC on the protection
oflaboratory animals.
Imnunization
A 2-AAF-gelatin conjugate (20) was used
as the immunogen. The immunization
procedure consisted of three weekly
intraperitoneal (ip) administrations of the
complete immunogen (50 pl of 2-AAF-
gelatin conjugate 1 mg/ml together with
50 PlI of Freund's adjuvant). A further
injection was delivered 14 days after the
third treatment. Controls received the
adjuvant alone or no treatment.
2-AAFTreatment
One week after the end of the immuniza-
tion, both immunized and nonimmunized
mice were fed 2-AAF pelleted in the diet at
50 and 150 ppm for 4 weeks. Parallel con-
trol groups were fed with the standard diet.
Determination of2-AAFAdducts
to Liver DNA
DNA Extraction. Livers frozen at -80°C
were thawed and homogenized in extrac-
tion buffer (10 mM Tris-HCl, pH 8.0,
100 mM EDTA, 0.5% sodium dodecyl
sulfate [SDS], 20 pg/ml RNAase) and
incubated 1 hr at 370C before the addition
of proteinase K (Sigma Chemical Co.,
St. Louis, MO) to a final concentration of
100 fig/mI. After 2 hr of incubation at
500 C, DNA was phenol extracted (21)
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and quantitated by 260 nm absorbance.
Protein and RNA contamination was
checked through theA260/A280 ratio.
Production ofthe Antiserum. The
anti-2-AAF immune serum was produced
by immunization of adult New Zeland
white rabbits with six weekly subcutaneous
injections of2-AAF-gelatin (1 mg) emulsi-
fied in complete Freund's adjuvant (0.5
ml). A 2 mg booster injection was delivered
15 days after the last inoculation. One week
later, the rabbits were bled from the heart.
Enzyme-linked Immunoadsorbent
Assays (ELISA). For the direct version of
the assay, polystyrene 96-well microtiter
plates were coated with 2-AAF-gelatin
conjugate (containing 0.05-0.5 ng 2-AAF).
Then, 50 pl of rabbit anti-2-AAF anti-
serum, diluted 2,500-fold, was added to
each well. Goat anti-rabbit immuno-
globulin G (IgG)-horseradish peroxidase
conjugate (Bio-Rad, Hercules, CA) was
used 1:2,000 as the second antibody with
o-phenylendiamine as the substrate (22).
DNA-2-AAF adducts were measured
by competitive ELISA (23,24). Briefly, 96
wells were coated with 0.25 ng 2-AAF-
gelatin and then saturated with 200 pl
of 0.5% gelatin. Standard curves were
obtained by adding to each well 50 pl of
rabbit antiserum diluted 1:5,000 that had
been preincubated 2 hr with serial dilutions
of2-AAF-gelatin as a competitor. For 2-
AAF-DNA adducts determination, 1.5 pg
of DNA was used as competitor. Goat
anti-rabbit IgG-horseradish peroxidase
conjugate was used as the second antibody
diluted 1:4,000, with o-phenylendiamine
as substrate.
Results and Discussion
To elicit a humoral response toward 2-AAF,
mice received repeated ip injections of a
complete immunogen, as detailed in the
previous section. Due to the low molecular
weight of the hapten (insufficient to pro-
duce an effective immunogenic stimulus) a
carrier molecule (gelatin) was conjugated
to 2-AAF. At the end ofimmunization, the
presence ofspecific IgG directed against
the 2-AAF-gelatin conjugate in the sera of
immunized mice was assessed by direct
ELISA. Although interindividual differ-
ences in serum titers were observed, all the
immunized mice examined produced
humoral antibodies capable of reacting
against the 2-AAF conjugate (Figure 1).
Conversely, serum pools of both non-
immunized mice and mice treated with the
adjuvant alone did not show any reactivity
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Figure 1. Reactivity of sera of immunized mice (n=37)
and pooled sera of nonimmunized mice (n=20) against
2-AAF-gelatin conjugate as determined by direct
ELISA. Plates were coated with 0.5 ng conjugate/well,
using 50 pl of 1% gelatin aqueous solution as the
blank. Sera were diluted 1:1,000. The bar represents
the standard error ofthe mean.
reactivity was observed against the carrier
protein alone (data not shown).
2AAF-DNA binding in livers of both
immunized and nonimmunized mice was
determined by competitive ELISA using a
polyclonal rabbit antiserum. This serum
was able to recognize the carcinogen
adducted to gelatin and bovine, egg, or
mouse serum albumin (Figure 2). Similar
results were obtained with pooled sera of
immunized mice (Figure 2). In both cases,
no reactivity was observed with the carrier
proteins alone (data not shown). As the
reactivity ofrabbit serum toward DNA and
protein adducts by competitive ELISA was
basically similar (Figure 3), the gelatin con-
jugate was used as quantitative standard in
all determinations.
The quantitation ofliver DNA adducts
after 4 weeks ofdietary exposure to 2-AAF
demonstrated high levels ofadducts in all
treated animals, with a partial quantitative
relationship with the administered dose
(Table 1). No reactivity was observed with
DNA ofuntreated mice (100% of reactiv-
ity in competitive ELISA), which was used
as an internal experimental control. A
comparison of the results obtained with
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Figure 2. Reactivity of mouse (solid lines) and rabbit
(dashed lines) sera against 2-AAF conjugated to differ-
ent carrier proteins: *, gelatin; *, mouse serum albu-
min; A, bovine serum albumin; *, ovalbumin. Rabbit
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Figure 3. Reactivity of rabbit polyclonal antiserum
toward 2-AAF adducted to gelatin (m) and DNA (0) as
determined by competitive ELISA. Plates were coated
with 0.25 ng 2-AAF-gelatin conjugate/well. The level
of modification of adducted DNA was 350 pg 2-AAF/pg
DNA. The antiserum was diluted 1:5,000.
(receiving either the vehicle or the adjuvant
alone) revealed a highly significant differ-
ence among groups, with far lower adduct
levels in immunized mice (Table 1). No
significant differences in food consumption
were observed between immunized and
nonimmunized mice, suggesting that all
animals received comparable amounts of
carcinogen at the end of treatment. Across
all the experimental groups, liver weights
were fairly similar; this suggested the
Table 1. Liver DNA adducts in mice following 4weeks dietary exposure to 2-AAF.
Pretreatment
Treatment(ppm) None Adjuvant Adjuvant and immunogen
50 101 ±9 (14) 115±15(11) 47±13(9)*
150 245±26(14) 162±19(12)** 62±13(12)#
Liver DNA adducts shown in fmol 2-AAF/pg DNA (mean±SE). Value in parentheses=n. Statistical significance of
differences observed among experimental groups was evaluated by the Student's t-test: *p<0.001 (vs nonimmu-
nized) and p<0.01 (vs adjuvant alone); **p<0.05 (vs nonimmunized); $p<0.001 (vs both nonimmunized and
adjuvant alone groups).
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absence of significant liver toxicity. The
possible indirect effect of immunization,
based on the impairment of liver enzymic
activities, was investigated in satellite
groups of immunized and nonimmunized
mice using liver homogenates for the
exogenous activation of2-AAF to mutagen
in the Salmonella reversion assay. Almost
identical results were obtained with homo-
genates from different experimental groups
(data not shown), indicating that the
immunization pretreatment did not exert
any significant detrimental effect on these
liver activities.
The mechanism underlying the intrigu-
ing result provided by this study is not yet
clear. As stated above, trivial bias due to a
perturbatory effect ofthe immunization on
liver functionality can be ruled out. Organ
weight, DNA and protein content, and
efficiency in the activation of 2-AAF to
bacterial mutagen were fairly similar in
immunized and nonimmunized mice. An
unspecific perturbation related to the stim-
ulation of the immune system is also
unlikely in view of the results obtained
with mice treated with the Freund's adju-
vant alone; these mice experienced a
significant yet unspecific immunogenic
stimulation. Therefore, alternative mecha-
nisms have to be considered. One plausible
explanation lies in the high reactivity ofthe
specific antibodies elicited by the immuni-
zation toward a variety ofcarcinogen con-
jugates. Considering that hydrophobic
carcinogens are largely present in the blood
stream in association with carrier proteins
(25), as are their reactive metabolites (26),
it is conceivable that circulating antibodies
may act as scavengers that effectively lower
the bioavailable fraction ofthe compound
entering into the organism.
It can be supposed that the production
of a specific humoral immunological
response after chronic carcinogen expo-
sure may be a widespread phenomenon.
Production ofspecific antibodies has been
observed in mice (27) and in humans
(28,29) with prolonged exposure to DNA-
damaging agents, suggesting that chronic
adduct formation on serum proteins or
DNA can fulfill the steric and structural
conditions required for the induction ofan
immune humoral response. In any case, no
definitive conclusion should be drawn on
the biological significance ofthe phenome-
non described herein. Further studies are
required to investigate its specificity, as
well as the profile of damage induced in
other target tissues. Nevetheless, the data
presented support the hypothesis that the
immunological response induced by chronic
exposures may act as a significant host
factor in environmental carcinogenesis.
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